OCRIPLASMIN(JETREA) is a recombinant truncated human serine protease plasmin with activity against fibronectin and laminin which are the components of normal vitreo-retinal interface.
- Phase II trials have shown that upto 3 injections of 125 micrograms of Ocriplasmin at monthly interval can lead to resolution of vitreo-macular traction and closure of macular hole (<400 microns) without serious complications.
- Less effective in VMTS + ERM or vitreomacular adhesions >1500 microns.
- Jetrea has not been studied extensively in Macular hole > 400 microns, myopia > 8D, axial length > 28mm, aphakia, history of rhegmatogenous RD, lens-zonule instability, proliferative diabetic retinopathy, ischemic retinopathy, retinal vein occulusions, wet AMD, vitreous hemorrhage. Hence, treatment is not recommended in these patients.
- No clinical data is available on its concurrent use with anti VEGF agents.
- Available as 0.5mg/0.2ml vial ,which is diluted in 0.2ml of 0.9% NaCl to get the final concentration of 125 micrograms/0.1ml.
- Stored at -20+/- 5 degree Clecius.
- Transient rise in IOP upto 60 minutes post injection and reduced optic nerve perfusion pressure.
- New macular hole formation or enlargement of pre-existing macular hole in strong adhesions.
- Infection
- Vitreous floaters
- Eye pain
- Photopsia
- Subconjunctival hemorrhage.
2 comments:
Thanks
Post a Comment